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Abstract
Background: Tuberculosis (TB) patients in Uganda incur large costs related to the illness, and while seeking and
receiving health care. Such costs create access and adherence barriers which affect health outcomes and increase
transmission of disease. The study ascertained the proportion of Ugandan TB affected households incurring
catastrophic costs and the main cost drivers.
Methods: A cross-sectional survey with retrospective data collection and projections was conducted in 2017. A
total of 1178 drug resistant (DR) TB (44) and drug sensitive (DS) TB patients (1134), 2 weeks into intensive or
continuation phase of treatment were consecutively enrolled across 67 randomly selected TB treatment facilities.
Results: Of the 1178 respondents, 62.7% were male, 44.7% were aged 15–34 years and 55.5% were HIV positive. For
each TB episode, patients on average incurred costs of USD 396 for a DS-TB episode and USD 3722 for a Multi drug
resistant tuberculosis (MDR TB) episode. Up to 48.5% of households borrowed, used savings or sold assets to defray
these costs. More than half (53.1%) of TB affected households experienced TB-related costs above 20% of their
annual household expenditure, with the main cost drivers being non-medical expenditure such as travel, nutritional
supplements and food.
Conclusion: Despite free health care in public health facilities, over half of Ugandan TB affected households
experience catastrophic costs. Roll out of social protection interventions like TB assistance programs, insurance
schemes, and enforcement of legislation related to social protection through multi-sectoral action plans with
central NTP involvement would palliate these costs.
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Background
Uganda is a high Tuberculosis/Human Immunodefi-
ciency Virus (TB/HIV) burden country, and the Tuber-
culosis prevalence survey conducted in 2014 put the
prevalence at 253 per 100,000 population [1] while data
available for 2018 puts the incidence at 200 per 100,000
population [2]. The TB incidence among HIV positive
individuals is 80 per 100,000 population while the mor-
tality among the HIV co-infected is 32/100,000 popula-
tion [3]. The proportion of multi drug resistant TB
(MDR TB) among the new TB cases and previously
treated TB cases is 1.6 and 12% respectively [3]. In 2018,
Uganda notified 52,458 TB patients and 65% of these
were male [4].
TB patients often navigate complex healthcare systems
before and after a TB diagnosis has been made. This
often results in them incurring large costs related to ill-
ness and disability, as well as seeking and receiving
health care. Low income countries like Uganda have TB
patients that face costs that could amount to half their
annual income [5] despite TB services being provided
free of charge in public health facilities [6]. In the private
health facilities, patients incur costs of screening and
diagnosis. For the private health facilities designated as
diagnostic and treatment units (DTU), the TB drugs are
provided free of charge. TB affects the poorest segment
of society disproportionately and the poverty-aggravating
effects of TB are therefore gravest for those who are
already vulnerable [7].
To cushion TB patients against the costs, the Global
TB Programme suggests several cross-sectoral measures
including increasing insurance coverage, reimburse-
ments, regulating and eliminating user fees, inclusion of
TB patients in social protection schemes among others
[7]. The end TB strategy has as one of the targets that
no TB-affected household should face catastrophic costs
due to tuberculosis care [8]. Catastrophic costs in most
surveys have been set at 20% of the household’s annual
income as this threshold is mostly associated with ad-
verse TB outcomes [9].
While some countries may attempt to provide free ser-
vices for TB related care, often only diagnostics and anti
TB drugs are free and patients may face other TB-related
expenses. Such include direct payments on transport,
symptom relieving medications, food and indirect expenses
due to lost income [9]. In Uganda, social protection services
(cash transfers, food support, social insurance, housing, so-
cial assistance) are limited, with the MDR TB patients being
prioritized. An unpublished report from one of the USAID
funded projects (Strengthening Uganda’s Systems for Treat-
ing AIDS Nationally- SUSTAIN) indicates that MDR TB
patients at the hospitals they support receive a refund of
United States Dollars (USD) 1.4 every time they come to
the health facility or a monthly lump sum of USD 32.0. The
median monthly wage for people in paid employment is
equivalent to USD 20.0 in rural areas and USD 57.0 in
urban areas [10].
This survey was designed to ascertain the proportion
of TB affected households experiencing catastrophic
costs and to identify cost drivers in order to guide pol-
icies on cost mitigation and delivery model improve-
ments. It measures the proportion of TB patients (and
their households) that experienced catastrophic total
cost in 2017.
Methods
This survey followed World Health Organization
(WHO) methodology and protocol design [7]. It was de-
signed as a cross-sectional survey design with retrospect-
ive data collection and projections. The survey was
conducted across TB diagnostic and treatment units
(DTU) which report to the national TB program and
were sampled through a cluster sampling strategy. A
sample size of 1174 patients was selected from 67 of the
1680 DTUs. Patients were consecutively enrolled as they
visited the health facility. Consecutive enrollment was
continued till the number of patients allocated to the
DTU was reached. In cases of children, the guardian ac-
companying them was interviewed and guardian costs
calculated. The guardian costs (direct non-medical and
direct medical) were included in the calculation of costs
if the guardian was part of the same household of the
patient. Clusters were allocated to 13 regions propor-
tionately according to the TB notification rates.
All consecutive Drug Sensitive TB (DS-TB) and multi
drug resistant TB (MDR-TB) patients registered for
treatment who were attending a sampled facility for a
follow-up visit (after a minimum of 2 weeks into the
present intensive or continuation treatment phase) were
interviewed using a questionnaire developed by WHO
[11], and reported on expenditures, time loss, measures
ability to pay (including assets ownership, household ex-
penditures and income) and coping mechanisms (taking
loans, selling assets, taking children out of school) retro-
spectively. Patients in each of the two treatment phases
were interviewed at different time points during their
treatment phase. Data collection for patients in different
treatment phases allowed for the imputation of data and
model projections of future and past costs during the
entire illness episode.
Costs of TB and MDR episodes
For each TB-affected household, total costs were calculated
as the sum of direct medical costs, direct non-medical costs
(transportation, accommodation, food, nutritional supple-
ments) and indirect costs after the onset of TB symptoms
and while in care as per WHO definitions [7]. Costs for
food and nutritional supplements included food required
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during hospitalization or food and nutritional supplements
recommended and additional to the regular food basket.
Patients were asked if they have had to buy any additional
food e.g. meat, fruits, energy drinks, or nutritional supple-
ments e.g. multivitamins outside their regular diet because
of TB as recommended by the health care staff.
Indirect costs were calculated using reported time
used while seeking and receiving care during the TB epi-
sode (in hours) multiplied by an individual hourly rate
derived from self-reported hourly income which was cal-
culated based on the reported individual income in con-
junction with the reported hours worked (so-called the
human capital approach) [7], assuming that hours lost
would have been used for a productive activity. Annual
household expenditures were calculated as the sum of
weekly, monthly and annual reported expenditures. The
household expenditure questions excluded consumption
that is not based on market transactions and included
validated questions from a household consumption sur-
vey questionnaire.
Catastrophic cost calculation
To ascertain the proportion experiencing catastrophic
costs, our main analysis used the human capital approach
paired with household expenditures as a measure of ability
to pay for health. Household expenditures were the money
payments or the incurrence of liability to obtain goods and
services. While we collected assets and reported income,
household expenditures appeared more robust as this could
easily be collected at the facility. Catastrophic costs were
calculated as total costs (indirect and direct combined) ex-
ceeding 20% of the household’s annual expenditure.
In addition to catastrophic cost calculations, data col-
lected allowed for assessment of dissaving strategies,
evaluation of risk factors for incurring catastrophic costs
and calculation of the proportion of TB-affected house-
holds below the poverty line (i.e. living on less than USD
1.9 per day) before and after contracting the disease
(impoverishment).
Impoverishment was calculated as the proportion of
households with daily expenditure below 6760 Uganda
Shillings (2017) which is equivalent to 1.90 US$ (2011
international poverty line). The proportion below pov-
erty (before TB) was calculated as the number with
monthly individual income (pre-TB) below the monthly
poverty threshold.
To obtain those pushed below poverty due to TB, we
added total costs (from output approach) to individual
income pre-TB, and checked the number falling below
the threshold.
Similarly, for those pushed below poverty level due to
direct medical and non-medical costs we added these
costs in and recalculated the proportion below threshold.
Data collection process and analysis
This facility-based survey collected data at 67 health fa-
cilities across the country. Data were collected electron-
ically by trained research assistants using a mobile and
web -based system (ONA, https://ona.io/home/) down-
loaded onto tablets, collected off-line and uploaded
when online. Part of the data collected was from TB
cards and registers while the rest were collected by inter-
viewing eligible patients at the facility for around 1 hour.
Data cleaning and analysis was done in Stata® Version
13 (StataCorp. 2013) in line with WHO minimum
reporting formats [7].
Results were adjusted for survey design and presented
by household expenditure quintiles where appropriate
(e.g. dissaving strategy).
Results
Table 1 shows the socio-demographic and clinical char-
acteristics of the respondents. The DS-TB respondents
were 1134 (96.2%) while the MDR-TB respondents were
44 (3.7%). Males, 739 (62.7%) were more than women,
439 (37.3%). Up to 362 (30.8%) respondents were in the
age group of 25–34 years and this accounted for the
highest number of respondents. The HIV positive re-
spondents in this survey were 654 (55.5%) while the re-
spondents that had previously been treated for TB were
103 (8.7%), with the proportion higher among the MDR-
TB patients; 28 (64%) than DS-TB patients; 75 (6.6%).
Up to 618 (52.5%) patients were interviewed while they
were in the continuation phase of TB treatment. Under
a half (48.3%) of the respondents had attained primary
school education.
Table 2 below highlights the model of care patients
were receiving at the time of interview i.e. whether they
were ambulatory or hospitalized. More MDR-TB pa-
tients than DS-TB patients were hospitalized i.e. 18
(41.9%) vs 74 (6.5%). The MDR-TB patients were hospi-
talized more times than the DS-TB patients (2 vs 1) and
on average, the MDR-TB patients were hospitalized for
91 days while the DS-TB patients were hospitalized for
13 days.
For ambulatory care and per TB episode, MDR-TB pa-
tients had more visits to the facilities than the DS-TB
patients (1093 vs 51). The number of directly observed
therapy (DOT) visits was 614.5 for the MDR-TB patients
compared to 167.6 for the DR-TB patients, with more
follow-up visits for the MDR-TB patients than the DR-
TB patients (10.9 vs 3.7).
Among the MDR-TB patients, treatment was delayed by
9.5 weeks compared to 9.9 weeks among the DS-TB pa-
tients with 3 (50.0%%) of the MDR-TB patients and 223
(45.9%) of DS-TB patients delaying treatment by 28 days.
Table 3 summarizes the costs the patients and their
guardians incurred both pre-diagnosis and post-diagnosis.
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N 44 1100 1134 43,413 1178 45,284
Socio-demographic characteristics of survey sample
Sex, N (%)
Male 30 (67.9%) 709 (62.5%) 739 (62.7%) 73%
Female 14 (32.1%) 425 (37.5%) 439 (37.3%) 28%
Age (%)
0–14 2 (5.1%) 54 (4.8%) 57 (4.8%) 10%
15–24 5 (11.3%) 159 (14%) 164 (13.9%) 90%
25–34 14 (31.3%) 349 (30.7%) 362 (30.8%)
35–44 11 (24.4%) 294 (25.9%) 304 (25.8%)
45–54 9 (21.5%) 159 (14.1%) 169 (14.3%)
55–64 0 (0%) 74 (6.5%) 74 (6.3%)
65+ 3 (6.6%) 45 (4%) 48 (4.1%)
Patient’s (guardian’s) education status %
Not yet started school 8 (18.8%) 151 (13.3%) 159 (13.5%)
Primary school 23 (53%) 546 (48.2%) 570 (48.3%)
Secondary school 12 (26.5%) 315 (27.8%) 327 (27.7%)
Tech/Tertiary School 0 (0%) 75 (6.6%) 75 (6.4%)
University and higher 1 (1.7%) 46 (4.1%) 47 (4%)
Occupation pre-disease
Professionals 2 (5.3%) 70 (6.2%) 72 (6.1%)
Technicians and associate professionals 0 (0%) 33 (2.9%) 33 (2.8%)
Clerical support workers 1 (2.8%) 7 (0.6%) 8 (0.7%)
Service and sales workers 15 (34.2%) 272 (24%) 287 (24.4%)
Skilled agricultural, forestry and fishery workers 0 (0%) 21 (1.8%) 21 (1.8%)
Craft and related trades workers 2 (4.3%) 56 (4.9%) 58 (4.9%)
Plant and machine operators, and assemblers 0 (0%) 6 (0.6%) 6 (0.5%)
Elementary occupations 4 (10.3%) 225 (19.8%) 229 (19.4%)
Armed forces 2 (3.6%) 14 (1.2%) 15 (1.3%)
Other 2 (3.9%) 76 (6.7%) 78 (6.6%)
Clinical Characteristics
Phase, N (%)
Intensive 18 (41.9%) 541 (47.7%) 560 (47.5%)
Continuation 25 (58.1%) 593 (52.3%) 618 (52.5%)
Recorded HIV Status, N (%)
Positive 25 (57.3%) 487 (42.9%) 654 (55.5%) 40%
Negative 19 (42.7%) 636 (56%) 512 (43.4%) 53%
Unknown 0 (0%) 12 (1.1%) 12 (1%) 7%
Retreatment status, N (%)
New 16 (36%) 1060 (93.4%) 1075 (91.3%)
Retreatment/Relapse 28 (64%) 75 (6.6%) 103 (8.7%)
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Pre-diagnosis, the biggest drivers of costs were medical
and travel for both MDR-TB and DS-TB. The biggest
drivers of costs after a TB diagnosis was made were nutri-
tional supplements (MDR-TB =US$ 1262, DS-TB =US$
189) followed by travel (MDR-TB =US$ 1019, DS-TB =
US$ 44) and food (MDR-TB =US$ 498, DS-TB =US$ 31).
The non-medical costs were the biggest contributor of the
costs for both types of TB. On average, it costs an MDR-
TB patient US$ 3722 for an entire episode of TB while for
DS-TB patients it costs US$ 396 for an entire TB episode.
Figure 1 highlights that the biggest costs for both types of
TB are direct non-medical followed by the indirect costs
and direct medical costs.
Table 4 shows the coping mechanisms (dissaving) that
the TB patients adopt to defray the TB costs, and also
shows the social consequences they encounter because
of TB. In the survey, up to 571(48.5%) patients used at
least one of the 3 dissaving strategies (took a loan, sold
assets or used savings) ranging from 536 (47.2%) for DS-
TB patients to 35 (81.2%) for MDR-TB. Regarding social
consequences, 585 (49.7%) experienced food insecurity,
477 (40.5%) lost a job, 140 (11.8%) had a child interrupt
schooling and 633 (53.7%) were socially excluded due to
TB and 94 (8%) had divorce or separation from a spouse.
The social consequences were worse for the patients in
the poorest income quintile and MDR-TB patients. Up
to 43.9% of survey households had received a form of so-
cial protection after a TB diagnosis was made, with the
proportion bigger for MDR-TB patients (56.4%) than for
the DS-TB patients (1.8%).
Table 5 presents the proportion of households experien-
cing catastrophic costs for different households. At a 20%
threshold, 614 (53.1%) participants experienced catastrophic
costs. The proportion experiencing catastrophic costs in-
creased with lower thresholds at 15 and 10% i.e., 62.4 and
75.2% respectively. The proportion of respondents experien-
cing catastrophic costs decreased with increased thresholds;
25 and 30% i.e. 45.2 and 38.9% respectively. Regarding direct
costs (direct medical and direct non-medical), 33.1% (383)
of the respondents spent up to 20% of their annual house-
hold income and the same trend as for catastrophic costs
was followed with changing thresholds.
In terms of direct medical costs, 3% (35) of the house-
holds used up to 20% of their annual income for these
costs. A similar trend of proportions was followed with
adjusted thresholds as for catastrophic costs (i.e., pro-
portions increasing/decreasing) with decreasing/increas-
ing thresholds.
Table 2 Model of care
MDR-TB DS-TB
44 1134
Mean (95% CI) Mean (95% CI)
Hospitalisation
Hospitalized at time of interview, N (%) 18 (41.9%) 74 (6.53%)
Previously hospitalized during current phase, N (%) 7 (16.7%) 125 (11.0%)
Times hospitalized during current phase, Mean (95% CI) 1.64 (0.83–2.45) 1.14 (1.04–1.23)
Mean duration (days) hospitalized during current phase (95% CI) 91.4 (0–199.2) 12.9 (10.1–15.8)
Median duration (days) hospitalized during current phase (IQR) 30 (26–102) 7 (5–14)
Ambulatory care
Number of visits per episode: total (95% CI) 1093.4 (917–1269.8) 51.2 (42.1–60.3)
Number of visits: DOT (95% CI) 614.5 (555.6–673.5) 167.6 (157.7–177.5)
Number of visits: follow-up (95% CI) 10.9 (0–22.5) 3.7 (3.1–4.3)
Number of visits: drug pick-up (95% CI) 569.1 (529.9–608.3) 9.1 (7.7–10.5)
Number of visits pre-diagnosis (95% CI) 1.6 (0.9–2.2) 1.1 (1.1–1.2)
Proportion of first visits to primary health facilities 5 (84.2%) 189 (39%)
Proportion of first visits from private facilities 2 (28.8%) 159 (32.8%)
Proportion of TB diagnoses made at private or NGO facility 2 (5%) 300 (26.5%)
Treatment duration
Treatment duration: intensive phase, weeks Mean (95% CI) 7 (6.1–7.9) 2 (2–2.1)
Treatment duration: continuation phase, weeks Mean (95% CI) 14.8 (12.8–16.8) 4.1 (4.1–4.1)
Treatment delay (among new patients in intensive phase) 6 486
Weeks of treatment delay Mean (95% CI) 9.5 (3.4–15.7) 9.9 (8.1–11.8)
Proportion of patients with delay > 28 days (%) 3 (50.0%) 223 (45.9%)
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Table 6 illustrates the risk factors for experiencing cata-
strophic costs. At both bivariate and multivariate analysis,
participants belonging to the poorest expenditure quintile
had higher odds of experiencing catastrophic costs i.e.
bivariate analysis: OR (IQR): 23.5 (12.9–42.7) and multi-
variate analysis: 24 (13.2–43.8). HIV, age and gender were
not associated with higher odds of experiencing cata-
strophic costs.
Figure 2 shows the impoverishment due to TB care.
Even before TB, 51.8% of the respondents were already
below the poverty level. Direct costs pushed an add-
itional 9.9% of the TB patients below the poverty level
Table 3 Estimated total costs borne by patients’ households affected by TB, MDR-TB or all, median breakdown (USD† 2017 (95% CI)
Costs MDR-TB Mean,95%CI DS-TB Mean,95%CI Overall Mean,95%CI
Pre-diagnosis Medical 4.11(0.27–7.94) 8.55(2.80–14.31) 8.50(2.79–14.20)
Travel 6.48(3.84–9.13) 2.10(1.39–2.81) 2.15(1.45–2.86)
Accommodation 0(0–0) 0.34(0.10–0.58) 0.34(0.10–0.57)
Food 0.69(0.41–0.97) 1.10(0.33–1.87) 1.09(0.33–1.85)
Nutritional supplements 0.44(0.15–0.73) 1.08(0.32–1.84) 0.80(0.20–1.41)
Hours lost by patient and guardian multiplied
by hourly wage
1.52(0.97–2.08) 1.7(0.67–2.72) 1.69(0.67–2.71)
Post-diagnosis Medical 78.7(12.5–145.0) 16.2(9.2–23.2) 18.5(11.2–25.9)
Travel 1019(896–1143) 43.9(34.0–53.7) 79.9(51.0–108.8)
Accommodation 0.4(0–1.1) 1.4(0–3.4) 1.4(0–3.3)
Food 498(353–642) 30.6(15.8–45.5) 47.9(25.8–70.1)
Nutritional supplements 1263.(928–1597) 189(151–227) 225(173–277)
Caregiver (guardian) costs 115(0–248) 25.2(14.7–35.7) 27.9 (17.3–38.5)
Hours lost by patient and guardian x Hourly wage 1219(537–1899) 115(96–135) 156(116–196)
Medical costs 79.3(12.7–146) 20.0(11.7–28.2) 22.2(15.0–30.4)
Non-medical costs 2239(1742–2737) 198(162–234) 273(199–347)
Indirect costs Human Capital Approach 1219(538–1901) 116.5(97–136) 157(117–197)
Dissaving/Coping Costs 183(19.0–348) 62.1(48.8–75.5) 66.6(50.3–83.0)
Total 3722(3071–4374) 396(337–456) 519(407–632)
Fig. 1 Average costs per TB episode
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while the indirect costs pushed an additional 2.6% below
the poverty level.
Discussion
This national TB cost survey established that up to 53% of
Ugandan TB affected households incur TB-related costs
that are higher than 20% of their annual household expen-
ditures, despite the free TB care policy. The survey also
identified the main cost drivers as non-medical expend-
iture such as travel, nutritional supplements and food.
The proportion of 53% of TB affected households ex-
periencing catastrophic costs is lower than was found in
Table 4 Dissaving mechanisms and social consequences for sample participants
Expenditure Quintilesa Treatment Group
Poorest Less Poor Average Less Wealthy Wealthiest Overall DS MDR
(N = 219) (N = 229) (N = 218) (N = 274) (N = 215) (N = 1178) (N = 1134) (N = 44)
Dissaving Strategies
Loan 22.8% 29.1% 27.6% 27% 25.6% 26.3% 25.9% 35.5%
Use of savings 6% 8.6% 12% 14.1% 14.9% 11.2% 10% 39.9%
Sale of assets 29.4% 27.6% 30.1% 25.1% 22% 26.5% 25.4% 54.4%
Any of the three above 45.5% 48.6% 54.3% 48.2% 47.6% 48.5% 47.2% 81.2%
Food insecurity 60.9% 48.6% 49.7% 50% 43.2% 49.7% 49.3% 59.7%
Divorce/separated from spouse/partner 8.7% 6.6% 10.5% 5.3% 9.2% 8% 7.8% 10.6%
Loss of Job 45.1% 44.3% 40.2% 34% 40.9% 40.5% 39.9% 56%
Child interrupted schooling 8.7% 10.7% 11% 11.6% 15.4% 11.8% 11.9% 11.5%
Social exclusion 60% 55.3% 51.4% 53.3% 50.8% 53.7% 54% 46.1%
Any days of work lost 16% 9.2% 4% 2.4% 5.7% 7.2% 4.4% 2.6%
Household received social protection
after TB diagnosis
3.2% 2.9% 5.1% 4.2% 3.5% 3.9% 1.8% 56.4%
a12 people excluded due to zero consumption data
Table 5 Households facing catastrophic costs
Expenditure quintiles a
Poorest Less Poor Average Less Wealthy Wealthiest Overall
(N = 219) (N = 229) (N = 218) (N = 274) (N = 215) (N = 1155)
Households experiencing total (direct and indirect) costs above (%) - Human capital Approach
10% 178 (81.4%) 162 (70.8%) 168 (77.2%) 214 (78.2%) 145 (67.5%) 868 (75.2%)
15% 157 (71.7%) 133 (58.4%) 141 (64.8%) 171 (62.4%) 118 (54.9%) 721 (62.4%)
20% 143 (65.4%) 106 (46.6%) 112 (51.3%) 152 (55.5%) 100 (46.4%) 613 (53.1%)
25% 119 (54.2%) 90 (39.4%) 98 (44.8%) 130 (47.4%) 86 (39.8%) 522 (45.2%)
30% 103 (47%) 76 (33.2%) 84 (38.7%) 117 (42.8%) 68 (31.7%) 449 (38.9%)
Number of households experiencing direct medical and non-medical costs above (%) annual household expenditure
10% 123 (56.1%) 106 (46.2%) 115 (52.9%) 140 (51.2%) 83 (38.6%) 567 (49.1%)
15% 107 (48.9%) 86 (37.5%) 95 (43.4%) 117 (42.6%) 61 (28.5%) 465 (40.3%)
20% 89 (40.7%) 69 (30.4%) 81 (37.2%) 95 (34.8%) 48 (22.2%) 383 (33.1%)
25% 82 (37.3%) 53 (23%) 72 (32.8%) 79 (28.9%) 40 (18.6%) 325 (28.1%)
30% 74 (33.9%) 46 (20.2%) 64 (29.4%) 67 (24.4%) 29 (13.3%) 280 (24.2%)
Number of households experiencing direct medical costs above (%) annual household expenditure
10% 18 (8%) 22 (9.6%) 14 (6.4%) 11 (4%) 7 (3.1%) 71 (6.1%)
15% 11 (5%) 12 (5.4%) 10 (4.3%) 9 (3.3%) 3 (1.4%) 45 (3.9%)
20% 9 (3.8%) 12 (5.4%) 6 (2.5%) 7 (2.6%) 1 (0.5%) 35 (3%)
25% 8 (3.4%) 11 (4.8%) 5 (2.3%) 6 (2.2%) 1 (0.5%) 30 (2.7%)
30% 8 (3.4%) 11 (4.8%) 5 (2.3%) 5 (1.7%) 1 (0.5%) 29 (2.5%)
a12 people excluded due to zero consumption data
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similar studies done in Vietnam, Ghana and Myanmar
[7, 12, 13] but higher than was found in Kenya and
Indonesia [14, 15]. This difference could be explained by
the differences in the geographic, health system and eco-
nomic profiles of the countries.
TB patients incur direct medical, direct non-medical
and indirect costs while they seek care. The study found
direct non-medical costs to be the biggest drivers of
catastrophic costs, with most of the costs incurred on
nutritional supplements, travel and food. This is consist-
ent with findings from similar surveys conducted else-
where [7, 14, 16]. Data from previous studies have
highlighted the contribution of food and transportation
to the nearest TB care service on indirect costs; putting
the figures at 50 and 37% respectively [17]. A study done
in Philippines found out that paying attention to the nu-
trition costs could reduce the catastrophic costs by 5%
[18]. In Uganda, MDR-TB patients receive enablers in
form of food and transport vouchers [19]. This survey
however shows that despite this, these patients still incur
high costs on nutrition and food. Potential solutions
could include increasing nutritional and transport sup-
port for MDR-TB patients and possibly introducing
similar support in the DS-TB patients.
The study found out DS-TB patients spent US$396 for
the entire TB episode while DR-TB patients spent up to
US$ 3722. Previous work done in Uganda on costs of
TB treatment analyzed from health services, patients and
community volunteers’ perspective showed the amount
needed to successfully treat a new smear-positive TB pa-
tient was US$ 911.0 and US$ 391.0 using the hospital-
based approach and community-based care approach re-
spectively [20]. The costs incurred by MDR-TB patients







15–24 0.6 (0.3–1.3) 0.4 (0.2–0.9)
25–34 0.7 (0.3–1.4) 0.5 (0.2–1)
35–44 0.7 (0.3–1.4) 0.5 (0.2–1)
45–54 0.6 (0.3–1.3) 0.4 (0.2–1)
55–64 0.9 (0.4–1.9) 0.5 (0.2–1.1)
65+ 1.2 (0.5–2.8) 0.7 (0.3–1.8)
Sex
Male 1 (0.8–1.4) 1 (0.7–1.3)
Female Reference Reference
Long delay (> 4 weeks
before diagnosis)
1.3 (0.9–2) 1.1 (0.7–1.8)
HIV Status
Positive 1 (0.7–1.4) 1 (0.7–1.3)
Negative Reference Reference
Expenditure Quintile
Poorest 23.5 (12.9–42.7) 24 (13.2–43.8)
Less Poor 6.1 (3.9–9.6) 6.2 (4–9.8)
Average 3.9 (2.7–5.8) 4 (2.7–5.9)
Less Wealthy 2.3 (1.6–3.5) 2.3 (1.5–3.4)
Wealthiest (Reference) Reference Reference
Fig. 2 Impoverishment headcount due to TB care
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in previous surveys have been found to be higher than
for DS-TB patients. In Ghana, costs per DS-TB episode
were US$429.6 while it was US$659.0 for MDR-TB pa-
tients [12]. The amount spent on TB treatment is high
in a setting like Uganda where the minimum monthly
wage is US$ 36 [21], and 21.4% of the population are
below the poverty level [22]. This survey established that
even before a TB diagnosis is made, 52% of the TB pa-
tients were already below the poverty level, with an add-
itional 12.5% pushed below the poverty level while in TB
care. These costs represent a large economic burden to
the Ugandan TB affected households, who are financially
compromised in the first place.
TB patients adopt several coping measures in a bid to
cushion against the TB-related costs. Close to half
(48.5%) of the patients had adopted at least one coping
mechanism. TB patient cost studies done elsewhere
found borrowing money and taking loans were the
widely used coping strategies for TB patients [5, 23].
The survey revealed respondents in the lowest income
quintiles (poorest, less poor and average) were more
likely to take up loans and sell assets as opposed to using
up their own savings. This is hardly surprising as this
group of patients do not normally have a stable income
source compared to individuals in the high-income
quintiles and thus hardly have any savings to draw upon.
TB patients encounter several social consequences
while in care. In this survey patients experience encoun-
tered food insecurity (49.7%), job loss (40.5%), interrup-
tion in schooling for children (11.8%) and social
exclusion (53.7%). The proportion experiencing these
consequences was higher than was found in similar sur-
veys [14, 16], and this could be due to differences in the
health care systems, sample sizes and economic profiles
of the countries.
In this survey, patients/households belonging in the
poorest expenditure quintile had higher odds of experi-
encing catastrophic costs. TB has often been known as a
disease of the poor since the burden follows a strong
socio-economic gradient, and also poor communities
have been known to have high incidences [23, 24]. TB
catastrophic costs are thus disproportionately experi-
enced by individuals who are already at a higher risk of
TB. Despite the high proportion of HIV/TB co-infected
patients in the survey, HIV didn’t increase the odds of
experiencing catastrophic costs. This possibly could be
due to the implementation of the one stop shop model
for TB/HIV services where TB and HIV services are of-
fered to the clients at the same time and location.
The survey results provide a baseline upon which fu-
ture catastrophic costs measurements could be com-
pared and progress towards the high-level End TB
Strategy target assessed. The survey results are disaggre-
gated by TB resistance status (i.e., DR TB and MDR
TB). However, the costs for the MDR TB patients need
to be appreciated in context of the low number sampled.
For example, the results showed costs incurred by the
MDR TB patients for a TB episode are 10 times higher
than for DS TB patients. It’s possible there is an over es-
timation for the MDR TB costs owing to the small num-
ber of MDR TB patients included in the survey. Despite
this, we believe the costs would still be higher even with
bigger numbers as has been seen in other studies that
have sampled more MDR TB patients [14, 16, 25].
Based on the survey findings, we recommend a policy
shift in order to be able to protect the TB patients against
catastrophic costs. This could include operationalization
of the national health/social insurance, strengthening and
enforcement of legislation related to social protection and
intersectoral collaborations as the effects span several
sectors.
Limitations
The survey included a few MDR-TB patients. Subsequent
surveys should purposely involve more MDR-TB patients
in the sample. Patients also were asked costs previously in-
curred which might have led to a recall bias. Recall bias
mainly affects cost estimates for the pre-treatment period
and the approach to only interview persons in intensive
phase about diagnostics costs was intended to minimize
this type of bias. Also, most of the costs were estimated as
the study was cross-sectional in nature. The survey also
did not include costs after treatment as some of the direct
and indirect costs of TB for the patients and the house-
hold can extend beyond the treatment period.
Conclusion
In conclusion, this survey established that over a half of
TB affected households in Uganda face catastrophic TB
care expenditure, with the major cost drivers being nu-
tritional supplements, travel, and food. This expenditure
results in adverse coping behaviors such as selling assets,
taking loans and using savings at high rates among the
patients.
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